Outcome: responses
. | Total, no (%) . | ABVD + RT, no (%) . | ABVD, no (%) . |
|---|---|---|---|
| Total | 152 | 76 | 76 |
| Assessable | 138 | 69 | 69 |
| Not assessable | 14* | 7 | 7 |
| CR | 130 (94) | 65 (94) | 65 (94) |
| PR | 1 (1) | 0 | 1 (1.5) |
| No major response | 7 (5) | 4 (6) | 3 (4.5) |
. | Total, no (%) . | ABVD + RT, no (%) . | ABVD, no (%) . |
|---|---|---|---|
| Total | 152 | 76 | 76 |
| Assessable | 138 | 69 | 69 |
| Not assessable | 14* | 7 | 7 |
| CR | 130 (94) | 65 (94) | 65 (94) |
| PR | 1 (1) | 0 | 1 (1.5) |
| No major response | 7 (5) | 4 (6) | 3 (4.5) |
Results include 1 protocol violation, 2 lost to follow-up, and 11 stage 1 with all measurable disease excised prior to treatment (see “Response to treatment and survival”).